Click here to view an updated version of this article.
NEW YORK, June 24 - Celera Diagnostics and Abbott Labs will partner to develop and market a "broad range" of in vitro molecular diagnostics to detect and monitor a variety of diseases, the companies said today.
Roughly 250 scientists and engineers from both firms will hunt markers to infectious diseases, cancer, central nervous system disorders, and cardiovascular and autoimmune diseases, the companies said.
Specifically, Celera Diagnostics will focus on discovering and validating genetic markers and developing assays while Abbott concentrates on product development, sales, and marketing, the partners said. The companies stressed they will not try to develop or commercialize proteins, immunoassays, or products for either the research or pharmaceutical markets.
Under the terms of the agreement, which reflects Celera Diagnostics' only alliance since it was formed slightly more than one year ago, the companies will share expenses and profits tied to researching, developing, manufacturing, and commercializing any products that may arise. Abbott also will distribute worldwide "most" products.
The partners agreed to share each other's technologies and patents; Abbott researchers will have access to Applied Biosystems' instruments and Celera Genomics' gene data and analytical tools, for example.
Celera said it plans to host a conference call tomorrow at 10:00 a.m. Eastern time. Click here for more information.